Price range: Above $1 billion
The scoop: ICU Medical ($ICUI) may not be the most exciting company in the medical device world, but the California outfit has been plugging away in the intravenous technology market for decades, last year growing its revenue 4.9% to $316.3 million. The company, founded by CEO George Lopez about 30 years ago, makes devices for infusion therapy, oncology and critical care, and it has been scaling up its R&D spending over the past year to expand its offerings. Back in May, reports surfaced that ICU had retained advisers and was looking to get bought, spurring a swirl of rumors that culminated in an early August report that the company had entered exclusive negotiations with Chicago private equity outfit GTCR. That triggered a one-day stock jump of nearly 10%, but things have quieted down ever since, and it's unclear whether the two are still talking.
Who wants it? If the GTCR negotiations have fallen apart, ICU and its growing share of the intravenous market would fit right in with competitors CareFusion ($CFN) and Hospira ($HSP), both rumored to have taken a look at buying the company. Each has been plagued by costly infusion pump recalls over the past year, and, from shareholders' perspective, ICU's steady revenue generation would likely be a welcome addition.
Report: ICU Medical nears sale that could top $1B
CareFusion emerges as potential ICU bidder
Report: ICU weighing billion-dollar sale